Ascendis Pharma A (ASND) Change in Receivables (2019 - 2026)

Ascendis Pharma A has disclosed Change in Receivables across 8 years of filings, most recently posting -$42.6 million for Q1 2026.

• Change in Receivables for Q1 2026 came in at -$42.6 million, down 141.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$19.6 million (down 81.21% YoY), and the FY2025 annual result was $135.7 million, up 207.08% from the prior year.
• Change in Receivables came in at -$42.6 million for Q1 2026 at Ascendis Pharma A, down from $106.5 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $106.5 million in Q4 2025 to a low of -$133.4 million in Q4 2024.
• The 5-year median for Change in Receivables is -$9.2 million (2023), against an average of -$5.3 million.
• Across the five-year window, Change in Receivables plunged 3786.48% in 2023 and jumped 941.05% in 2025, its largest moves.
• Ascendis Pharma A's Change in Receivables stood at -$5.6 million in 2022, then sank by 64.71% to -$9.2 million in 2023, then sank by 1354.25% to -$133.4 million in 2024, then soared by 179.82% to $106.5 million in 2025, then slumped by 140.01% to -$42.6 million in 2026.
• The last three Change in Receivables figures came in at -$42.6 million (Q1 2026), $106.5 million (Q4 2025), and -$29.1 million (Q3 2025), per Business Quant data.